Nuvastatic
Sponsors
Natureceuticals Sdn Bhd
Conditions
Covid19Diabetic Retinopathy
Phase 1
To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.
NCT04542447
Start: 2020-09-01End: 2020-09-30Target: 10Updated: 2020-09-10
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
CompletedNCT04552600
Start: 2019-09-01End: 2022-08-10Updated: 2025-12-12